Tidemark LLC Takes $31,000 Position in Novo Nordisk A/S (NYSE:NVO)

Tidemark LLC bought a new stake in shares of Novo Nordisk A/S (NYSE:NVO) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 300 shares of the company’s stock, valued at approximately $31,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in NVO. Westside Investment Management Inc. grew its stake in Novo Nordisk A/S by 83.3% in the third quarter. Westside Investment Management Inc. now owns 1,428 shares of the company’s stock worth $130,000 after purchasing an additional 649 shares in the last quarter. Lazard Asset Management LLC boosted its holdings in shares of Novo Nordisk A/S by 182.2% during the third quarter. Lazard Asset Management LLC now owns 1,494,214 shares of the company’s stock valued at $135,883,000 after acquiring an additional 964,640 shares during the period. Ieq Capital LLC boosted its stake in Novo Nordisk A/S by 136.6% during the 3rd quarter. Ieq Capital LLC now owns 27,474 shares of the company’s stock valued at $2,498,000 after purchasing an additional 15,860 shares during the period. One Capital Management LLC acquired a new stake in shares of Novo Nordisk A/S in the third quarter valued at approximately $203,000. Finally, Advisor Resource Council acquired a new position in shares of Novo Nordisk A/S during the fourth quarter worth approximately $997,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 0.3 %

NVO traded up $0.47 during mid-day trading on Friday, hitting $136.04. The stock had a trading volume of 2,845,222 shares, compared to its average volume of 4,075,833. Novo Nordisk A/S has a 1-year low of $75.56 and a 1-year high of $138.28. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.70 and a quick ratio of 0.50. The stock’s fifty day simple moving average is $128.21 and its 200-day simple moving average is $116.45. The firm has a market capitalization of $610.48 billion, a price-to-earnings ratio of 46.91, a price-to-earnings-growth ratio of 1.40 and a beta of 0.43.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Thursday, May 2nd. The company reported $0.83 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.06. The company had revenue of $9.52 billion for the quarter, compared to analyst estimates of $9.23 billion. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 91.70%. As a group, research analysts forecast that Novo Nordisk A/S will post 3.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on NVO shares. BMO Capital Markets started coverage on shares of Novo Nordisk A/S in a report on Friday, April 12th. They issued an “outperform” rating and a $163.00 price objective for the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Thursday, April 18th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Moderate Buy” and a consensus target price of $133.60.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.